2020
DOI: 10.15825/1995-1191-2020-1-118-122
|View full text |Cite
|
Sign up to set email alerts
|

Levosimendan in lung transplant recipients on VA‑ECMO

Abstract: Chronic heart failure is one of the most dreadful complications in the early postoperative period following lung transplantation. At the same time, the effect of using levosimendan in the early post-lung transplant period is currently insignificant and remains debatable. This paper presents a clinical case where levosimendan was successfully used in a patient with right ventricular heart failure during lung transplantation undergoing central venoarterial extracorporeal membrane oxygenation (VA-ECMO).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 13 publications
(6 reference statements)
0
1
0
Order By: Relevance
“…Individual case reports showed possible advantages for levosimendan. For example, the use of this drug led to better weaning of VA ECMO therapy in the context of RVF [ 63 , 64 ]. The administration of levosimendan may also lead to positive effects on left ventricular diastolic function.…”
Section: Strategymentioning
confidence: 99%
“…Individual case reports showed possible advantages for levosimendan. For example, the use of this drug led to better weaning of VA ECMO therapy in the context of RVF [ 63 , 64 ]. The administration of levosimendan may also lead to positive effects on left ventricular diastolic function.…”
Section: Strategymentioning
confidence: 99%